Login Register Cart 0
Generic placeholder image

Current Molecular Medicine

Editor-in-Chief

ISSN (Print): 1566-5240
ISSN (Online): 1875-5666

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in Chinese
Research Article

Homocysteine Serum Levels as Prognostic Marker of Hepatocellular Carcinoma with Portal Vein Thrombosis

Author(s): Saverio Latteri, Giulia Malaguarnera, Vito Emanuele Catania*, Gaetano La Greca, Gaetano Bertino, Antonio Maria Borzì, Filippo Drago and Michele Malaguarnera

Volume 19, Issue 7, 2019

Page: [532 - 538] Pages: 7

DOI: 10.2174/1566524019666190610120416

Price: $65

Abstract

Background: Portal vein thrombosis (PVT) is a common complication of endstage hepatocellular carcinoma (HCC).

The aim of our study was to evaluate the role of Homocysteine (Hcy) in HCC patient with PVT. Hcy is a sulphur amino-acid involved in two pathways, trans-sulphuration and remethylation, that involve vitamins B6, B12 and folates.

Methods: We recruited 54 patients with HCC and PVT, 60 patients with HCC and without PVT and 60 control subjects. We measured serum levels of Hcy, folate, vitamins B6 and B12.

Results: The comparison between HCC patients with PVT versus HCC without PVT was shown that mean values of Hcy were 6.4 nmol/L (p<0.0073) higher, LDL cholesterol were 4.8 mg/dl (p<0.0079) lower, vitamin B6 were 4.6 nmol/L(p=0.0544) lower, vitamins B 12 were 22.1 pg/ml (p=0.0001) lower.

Conclusion: High serum levels of Hcy are an established thrombotic risk factor in the general population. We found significantly higher levels of Hcy in HCC patients with PVT versus both HCC patients without PVT and controls.

Keywords: Homocysteine, Vitamin B12, Vitamin B6, Folate, Hepatocellular Carcinoma, Portal Vein thrombosis, Epigenetic.

« Previous
[1]
Malaguarnera G, Gagliano C, Giordano M, et al. Homocysteine serum levels in diabetic patients with non proliferative, proliferative and without retinopathy. BioMed Res Int 2014; 2014: 191497.
[2]
Selhub J, Jacques PF, Bostom AG, et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med 1995; 332(5): 286-91.
[3]
Finkelstein JD. The metabolism of homocysteine: pathways and regulation. Eur J Pediatr 1998; 157(Suppl. 2): S40-4.
[4]
Selhub J. Homocysteine metabolism. Annu Rev Nutr 1999; 19: 217-46.
[5]
Bruix J, Reig M, Rimola J, et al. Clinical decision making and research in hepatocellular carcinoma: pivotal role of imaging techniques. Hepatology 2011; 54(6): 2238-44.
[6]
Chan SL, Chong CC, Chan AW, Poon DM, Chok KS. Management of hepatocellular carcinoma with portal vein tumor thrombosis: Review and update at 2016. World J Gastroenterol 2016; 22(32): 7289-300.
[7]
Joseph J, Handy DE, Loscalzo J. Quo vadis: whither homocysteine research? Cardiovasc Toxicol 2009; 9(2): 53-63.
[8]
Feinberg AP. Phenotypic plasticity and the epigenetics of human disease. Nature 2007; 447(7143): 433-40.
[9]
Wang H, Yoshizumi M, Lai K, et al. Inhibition of growth and p21ras methylation in vascular endothelial cells by homocysteine but not cysteine. J Biol Chem 1997; 272(40): 25380-5.
[10]
Bosy-Westphal A, Petersen S, Hinrichsen H, Czech NJ, Müller M. Increased plasma homocysteine in liver cirrhosis. Hepatol Res 2001; 20(1): 28-38.
[11]
Undas A, Williams EB, Butenas S, Orfeo T, Mann KG. Homocysteine inhibits inactivation of factor Va by activated protein C. J Biol Chem 2001; 276(6): 4389-97.
[12]
den Heijer M, Rosendaal FR, Blom HJ, Gerrits WB, Bos GM. Hyperhomocysteinemia and venous thrombosis: a meta-analysis. Thromb Haemost 1998; 80(6): 874-7.
[13]
den Heijer M, Brouwer IA, Bos GM, et al. Vitamin supplementation reduces blood homocysteine levels: a controlled trial in patients with venous thrombosis and healthy volunteers. Arterioscler Thromb Vasc Biol 1998; 18(3): 356-61.
[14]
Malaguarnera G, Catania VE, Francaviglia A, et al. Lipoprotein(a) in patients with hepatocellular carcinoma and portal vein thrombosis. Aging Clin Exp Res 2017; 29(Suppl. 1): 185-90.
[15]
Uccello M, Malaguarnera G, Pelligra EM, Biondi A, Basile F, Motta M. Lipoprotein(a) as a potential marker of residual liver function in hepatocellular carcinoma. Indian J Med Paediatr Oncol 2011; 32(2): 71-5.
[16]
Bertino G, Malaguarnera G, Frazzetto E, et al. Responsibility of hepatitis C virus in the development of hepatocellular carcinoma: From molecular alterations to possible solutions. World J Hepatol 2018; 10(6): 448-51.
[17]
Gatt A, Makris M. Hyperhomocysteinemia and venous thrombosis. Semin Hematol 2007; 44(2): 70-6.
[18]
Coull BM, Malinow MR, Beamer N, Sexton G, Nordt F, de Garmo P. Elevated plasma homocyst(e)ine concentration as a possible independent risk factor for stroke. Stroke 1990; 21(4): 572-6.
[19]
Vecchio M, Gracies JM, Panza F, et al. Change in Coefficient of Fatigability Following Rapid, Repetitive Movement Training in Post-Stroke Spastic Paresis: A Prospective Open-Label Observational Study. J Stroke Cerebrovasc Dis 2017; 26(11): 2536-40.
[20]
Mangia A, Villani MR, Cappucci G, et al. Causes of portal venous thrombosis in cirrhotic patients: the role of genetic and acquired factors. Eur J Gastroenterol Hepatol 2005; 17(7): 745-51.
[21]
Gayowski TJ, Marino IR, Doyle HR, et al. A high incidence of native portal vein thrombosis in veterans undergoing liver transplantation. J Surg Res 1996; 60(2): 333-8.
[22]
Malaguarnera M, Latteri S, Bertino G, et al. D-dimer plasmatic levels as a marker for diagnosis and prognosis of hepatocellular carcinoma patients with portal vein thrombosis. Clin Exp Gastroenterol 1996; 11: 373-80.
[23]
Malaguarnera M, Catania VE, Borzì AM, et al. Blood homocysteine levels are increased in hepatocellular carcinoma patients with portal vein thrombosis. A single centre retrospective cohort study. International Journal of Surgery Open 2018; 15: 60-5.
[24]
Brattström LE, Israelsson B, Jeppsson JO, Hultberg BL. Folic acid--an innocuous means to reduce plasma homocysteine. Scand J Clin Lab Invest 1988; 48(3): 215-21.
[25]
Omata M, Lesmana LA, Tateishi R, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010; 4(2): 439-74.
[26]
A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998; 28(3): 751-5.
[27]
Daniele B, Annunziata M, Barletta E, Tinessa V, Di Maio M. Cancer of the Liver Italian Program (CLIP) score for staging hepatocellular carcinoma. Hepatol Res 2007; 37(Suppl. 2): S206-9.
[28]
Malaguarnera G, Bertino G, Vacante M, Malaguarnera M. Hepatocellular carcinoma markers in the omics era: the glycomic analysis. Hepatobiliary Surg Nutr 2014; 3(6)(Suppl. 2): 407-9.
[29]
Lynch SM, Campione AL, Moore MK. Plasma thiols inhibit hemin-dependent oxidation of human low-density lipoprotein. Biochim Biophys Acta 2000; 1485(1): 11-22.
[30]
Bosy-Westphal A, Ruschmeyer M, Czech N, et al. Determinants of hyperhomocysteinemia in patients with chronic liver disease and after orthotopic liver transplantation. Am J Clin Nutr 2003; 77(5): 1269-77.
[31]
Córdoba-Porras A, Sánchez-Quesada JL, González-Sastre F, Ordóñez-Llanos J, Blanco-Vaca F. Susceptibility of plasma low- and high-density lipoproteins to oxidation in patients with severe hyperhomocysteinemia. J Mol Med (Berl) 1996; 74(12): 771-6.
[32]
Werstuck GH, Lentz SR, Dayal S, et al. Homocysteine-induced endoplasmic reticulum stress causes dysregulation of the cholesterol and triglyceride biosynthetic pathways. J Clin Invest 2001; 107(10): 1263-73.
[33]
Bestor TH. The DNA methyltransferases of mammals. Hum Mol Genet 2000; 9(16): 2395-402.
[34]
Klose RJ, Bird AP. Genomic DNA methylation: the mark and its mediators. Trends Biochem Sci 2006; 31(2): 89-97.
[35]
Rapisarda V, Loreto C, Malaguarnera M, et al. Hepatocellular carcinoma and the risk of occupational exposure. World J Hepatol 2016; 8(13): 573-90.
[36]
Latteri S, Malaguarnera G, Mannino M, et al. Ultrasound as point of care in management of polytrauma and its complication. J Ultrasound 2017; 20(2): 171-7.
[37]
Latteri S, Catania VE, Malaguarnera G, et al. Carcinoembryonic Antigen Serum Levels in Nonmelanoma Skin Cancer. Biomedicines 2018; 6(1): 24.
[38]
Gauthier GM, Keevil JG, McBride PE. The association of homocysteine and coronary artery disease. Clin Cardiol 2003; 26(12): 563-8.
[39]
Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993; 270(22): 2693-8.
[40]
Saibeni S, Cattaneo M, Vecchi M, et al. Low vitamin B(6) plasma levels, a risk factor for thrombosis, in inflammatory bowel disease: role of inflammation and correlation with acute phase reactants. Am J Gastroenterol 2003; 98(1): 112-7.
[41]
McCarty MF. Increased homocyst(e)ine associated with smoking, chronic inflammation, and aging may reflect acute-phase induction of pyridoxal phosphatase activity. Med Hypotheses 2000; 55(4): 289-93.
[42]
Uccello M, Malaguarnera G, Corriere T, Biondi A, Basile F, Malaguarnera M. Risk of hepatocellular carcinoma in workers exposed to chemicals Hepat Mon . 2012; 12(10 HCC): e5943.
[43]
Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998; 338(15): 1042-50.

Rights & Permissions Print Cite
Article Metrics
42
2
1
© 2024 Bentham Science Publishers | Privacy Policy